Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03909971 |
| Consolidated Lead Sponsor | Pfizer |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 109 participants (ACTUAL) |
| Registered Start Date | 2019-04-28 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Beijing Cancer Hospital | Beijing, China | Open Hospital Dossier -> |
| Harbin Medical University Cancer Hospital | Harbin, China | Open Hospital Dossier -> |
| The First Hospital of Jilin University | Changchun, China | Open Hospital Dossier -> |
| Zhejiang Cancer Hospital | Hangzhou, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.